Black Diamond Therapeutics, Inc.
US ˙ NasdaqGS ˙ US09203E1055

SecurityBDTX / Black Diamond Therapeutics, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership564,838 shares
Latest Disclosed Value $ 1,203,105
UBS Group AG reports 119.24% increase in ownership of BDTX / Black Diamond Therapeutics, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 564,838 shares of Black Diamond Therapeutics, Inc. (US:BDTX) valued at $1,203,105 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 257,633 shares of Black Diamond Therapeutics, Inc.. This represents a change in shares of 119.24% during the quarter. The current value of the position is $1,180,511 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 564,838 307,205 119.24 1,203 92.17 0.0000
2026-01-29 2025-12-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 257,633 -370,783 -59.00 626 -73.71 0.0000
2025-11-13 2025-09-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 628,416 314,716 100.32 2,382 206.44 0.0004
2025-08-14 2025-06-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 313,700 185,906 145.47 778 292.42 0.0001
2025-05-13 2025-03-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 127,794 77,901 156.14 198 86.79 0.0000
2025-02-14 2024-12-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 49,893 11,436 29.74 107 -36.53 0.0000
2024-11-14 2024-09-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 38,457 11,923 44.93 167 35.77 0.0000
2024-08-14 2024-06-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 26,534 22,263 521.26 124 485.71 0.0000
2024-05-13 2024-03-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 4,271 284 7.12 22 90.91 0.0000
2024-02-09 2023-12-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 3,987 3,741 1,520.73 11 0.0000
2023-11-09 2023-09-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 246 -8,273 -97.11 1 -100.00 0.0000
2023-08-11 2023-06-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 8,519 8,519 43 0.0000
2023-05-12 2023-03-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 0 -3,433 -100.00 0 -100.00
2023-02-08 2022-12-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 3,433 -1,942 -36.13 6 -33.33 0.0000
2022-11-10 2022-09-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 5,375 -12,224 -69.46 9 -79.55 0.0000
2022-08-10 2022-06-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 17,599 -3,221 -15.47 44 -24.14 0.0000
2022-05-16 2022-03-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 20,820 -8,734 -29.55 58 -63.06 0.0000
2022-02-14 2021-12-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 29,554 12,733 75.70 157 9.79 0.0000
2021-11-15 2021-09-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 16,821 5,454 47.98 143 2.88 0.0000
2021-08-13 2021-06-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 11,367 -31,822 -73.68 139 -86.74 0.0000
2021-05-12 2021-03-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 43,189 43,189 1,048 0.0003
2021-02-11 2020-12-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 0 -197 -100.00 0 -100.00
2020-11-12 2020-09-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 197 -4,457 -95.77 6 -96.94 0.0000
2020-07-31 2020-06-30 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 4,654 -2,577 -35.64 196 8.89 0.0001
2020-05-01 2020-03-31 13F BLACK DIAMOND THERAPEUTICS I COM 09203E105 7,231 7,231 180 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.